ACW September 2026 quarterly activity report & Appendix 4C

• Pivotal Alzheimer's disease XanaMIA trial on track for topline results in November
• 87% of main trial participants enrolled in open-label extension phase
• Actinogen secures additional $5.3 million from option exercises
• Cash balance of $21.9 million extends runway to late CY2027 or CY2028

Actinogen Medical Ltd has released its quarterly activity report for the three months ended 30 September 2026, highlighting progress in its pivotal XanaMIA phase 2b/3 Alzheimer's disease trial, which is on track for topline results in November. The open-label extension (OLE) phase of the trial has seen 87% of main trial participants enrolling, providing extended safety data and observational information on key efficacy endpoints. The company has also secured additional funding of $5.3 million from option exercises and underwriting, and its cash balance of $21.9 million provides a runway extending to late CY2027 or CY2028. Actinogen continues to pursue strategic partnerships and is preparing for potential regulatory interactions post-trial results.

Actinogen expects topline results from the XanaMIA trial in November 2026.

Actinogen is preparing for the potential launch of Xanamem as a treatment for Alzheimer's disease, with a focus on securing partnerships and regulatory approvals.